Ibuprofen And Famotidine Tablet
Product Images NDC 31722-315

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Ibuprofen And Famotidine (NDC 31722-315). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

5.11 (5.11)

A text panel describing risks associated with the use of NSAIDs, including ibuprofen and famotidine tablets, during pregnancy at about 30 weeks gestation or later, such as premature closure of the fetal ductus arteriosus and oligohydramnios or neonatal renal impairment.*

FDA Label Image

5.14 (5.14)

A drug facts panel discussing precautions related to ibuprofen use during pregnancy. It covers the risks of premature closure of the fetal ductus arteriosus, oligohydramnios, neonatal renal impairment, and methodological limitations of postmarketing studies. It also highlights potential neonatal complications when NSAIDs delay preterm labor, including risks of necrotizing enterocolitis and intracranial hemorrhage.*

FDA Label Image

90s (60mlbt)

Label for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg strength, by Camber Pharmaceuticals, Inc. The label includes the NDC number 31722-315-90 and indicates the package contains 90 tablets for oral use. It also notes prescription-only status and provides manufacturer and storage information.*

FDA Label Image

Ibu-struct.jpg (Ibu Struct)

Chemical structure diagram of the active ingredient ibuprofen showing its molecular framework with a benzene ring and associated functional groups.*

FDA Label Image

Mg 2 (Mg2)

A text panel listing potential serious side effects related to the drug Ibuprofen and Famotidine, including heart attack, stroke, liver problems with liver failure, worsening high blood pressure, heart failure, kidney problems including kidney failure, life-threatening allergic reactions, asthma attacks in asthmatic patients, life-threatening skin reactions, and low red blood cells (anemia).*

FDA Label Image

Mg 3 (Mg3)

A partial text panel listing symptoms including shortness of breath, chest pain, weakness on one side of the body, slurred speech, and swelling of the face or throat, likely part of a warnings or side effects section associated with the drug Ibuprofen and famotidine tablets by Camber Pharmaceuticals.*

FDA Label Image

Mg 4 (Mg4)

A text panel listing potential side effects or symptoms to watch for, including nausea, diarrhea, itching, yellowing of skin or eyes, indigestion, flu-like symptoms, vomiting blood, blood in bowel movements, unusual weight gain, skin rash with fever, and swelling of arms, legs, hands, and feet.*

FDA Label Image

Famotidine-struct.jpg (Famotidine Struct)

Chemical structure of the active ingredient famotidine as shown in the image. The diagram depicts the molecular structure with labeled atoms and bonds characteristic of famotidine.*

FDA Label Image

Mg 1 (Mg 1if)

This text panel provides warnings related to increased risks of heart attack, stroke, bleeding, ulcers, and esophageal tears associated with the use of ibuprofen and famotidine tablets. It highlights risk factors such as dosage, duration of NSAID use, past medical history, and other conditions that may increase these risks.*

FDA Label Image

Table 1 (Table 1)

A data table titled 'Shift Table of Serum Creatinine, Normal to Abnormal in Controlled Studies,' presenting percentages and counts of serum creatinine shifts at baseline and post-baseline for Ibuprofen and Famotidine tablets versus Ibuprofen alone in studies 301 and 303. The table includes definitions of normal and abnormal serum creatinine ranges.*

FDA Label Image

Table 2.2 (Table 2.2)

A table comparing the number of reported cases of various disorders, including musculoskeletal, nervous system, respiratory, and vascular disorders, such as arthralgia, back pain, headache, cough, pharyngolaryngeal pain, and hypertension.*

FDA Label Image

Table 2.1 (Table 2)

Table showing incidence of adverse reactions in controlled studies comparing ibuprofen and famotidine tablets (N=1022) versus ibuprofen alone (N=511). Reactions are categorized by system disorder types with percentage incidences listed side-by-side for each treatment group.*

FDA Label Image

Table 3.1 (Table 3.1)

This panel discusses drug interactions related to hemostasis for the drug combination Ibuprofen and Famotidine. It covers clinical impacts and interventions concerning concomitant use with anticoagulants such as warfarin and antiplatelet agents like aspirin, including risks of increased bleeding and cardiovascular events. It advises monitoring and cautious use with these medications along with reference to warnings and precautions.*

FDA Label Image

Table 3.2 (Table 3.2)

A text panel detailing clinical impact and intervention guidelines for drug interactions involving ibuprofen and famotidine tablets with various drug classes. It covers ACE inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, digoxin, lithium, and methotrexate, focusing on effects such as blood pressure impact, renal function, drug concentration monitoring, and toxicity risks during concomitant use.*

FDA Label Image

Table 3.3 (Table 3.3)

This image is a text panel listing drug interaction warnings and clinical impacts related to ibuprofen and famotidine. It details the effects and recommended monitoring for concomitant use with drugs like cyclosporine, other NSAIDs, pemetrexed, gastric pH-dependent drugs, and tizanidine. The panel provides clinical impact summaries along with intervention guidance.*

FDA Label Image

Tab4 (Table 4)

A data table titled 'Overall Incidence Rates of Patients Who Developed at Least One Upper Gastrointestinal or Gastric Ulcer - Study 301.' It compares incidence rates between patients treated with ibuprofen and famotidine tablets versus ibuprofen alone. The table includes percentages, patient numbers, and P-values for primary and secondary endpoints, specifically upper gastrointestinal ulcers and gastric ulcers, using different classification criteria.*

FDA Label Image

Tab5 (Table 5)

Table showing the overall incidence rate of patients developing at least one gastric or upper gastrointestinal ulcer in Study 303, comparing Ibuprofen and famotidine tablet versus Ibuprofen alone. It includes primary and secondary endpoints with percentage and sample size (n/N) and P-values indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.